C4 Therapeutics(US:CCCC)2025-05-07 11:06Financial Performance - Total revenue for Q1 2025 was $7.2 million, a 139% increase from $3.0 million in Q1 2024, primarily due to collaborations with Merck KGaA and Roche[10] - Net loss for Q1 2025 was $26.3 million, an improvement from a net loss of $28.4 million in Q1 2024, with net loss per share decreasing to $0.37 from $0.41[13] - Cash, cash equivalents, and marketable securities totaled $234.7 million as of March 31, 2025, expected to fund operations into 2027[14] - Research and development (R&D) expenses for Q1 2025 were $27.1 million, up from $22.5 million in Q1 2024, mainly due to clinical trial expenses[11] - General and administrative (G&A) expenses decreased to $9.3 million in Q1 2025 from $10.3 million in Q1 2024, reflecting reduced personnel costs[12] Clinical Development - Cemsidomide demonstrated a 50% overall response rate (ORR) at the 100 µg dose level, with one patient achieving a minimal residual disease negative complete response[3][4] - At the 75 µg dose level, Cemsidomide achieved an ORR of 40% with 20 patients treated[8] - The company expects to receive regulatory feedback on Cemsidomide's registrational development by mid-year 2025[8] - Upcoming data presentations include completed Cemsidomide Phase 1 dose escalation in multiple myeloma in Q3 2025 and in non-Hodgkin's lymphoma in Q4 2025[8] Strategic Plans - C4 Therapeutics plans to seek partnership opportunities to advance the BRAF program after deciding not to progress CFT1946 beyond the current Phase 1 trial[17]